Sectors
Health, Analytics, BioTech
Headquarters
San Francisco, CA, USA
CEO
Mike Nolan
Freenome shares, as of April 21, 2025, are valued at a price per share implying an approximate +21.73% relative to the most recent significant secondary market activity in March 2025, according to PM Insights' market data. PM Insights uses a market-driven derived price methodology to determine Freenome's valuation when recent secondary market transactions are limited or unavailable, as is currently the case for Freenome.
Register today to view the full report, with more in-depth details and analytics
Latest funding round
XXXXX
XX-XX-XXXX
AV Implied Valuation
XXXXX
XX-XX-XXXX
Change since Last Round
XXXXX
XX-XX-XXXX
Secondary Activity
XXXXX
Business Partnerships
Targeted Impact
Who Will Benefit?
What Comes Next?
No items found.
.png)
Freenome shares, as of April 21, 2025, are valued at a price per share implying an approximate +21.73% relative to the most recent significant secondary market activity in March 2025, according to PM Insights' market data. PM Insights uses a market-driven derived price methodology to determine Freenome's valuation when recent secondary market transactions are limited or unavailable, as is currently the case for Freenome.
Freenome's mutual fund disclosures indicate a three-month moving average fund price per share of $5.59 as of February 27, 2025, according to PM Insights' market data.
No items found.
No items found.
Ready to see it in action?
Schedule a demo with one of our experts
